Stock DOVA DOVA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Dova Pharmaceuticals, Inc.

Equities

DOVA

US25985T1025

Delayed Nasdaq
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Dova Pharmaceuticals, Inc. -0.07% +269.92%
2019 Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag CI
2019 Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag
CI
Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase
CI
Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
CI
Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia
CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index
CI
Dova Pharmaceuticals, Inc. Announces Executive Changes
CI
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.
CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index
CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index
CI
Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index
CI
WeissLaw LLP Investigates Dova Pharmaceuticals, Inc.
PR
Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
GL
Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.
CI
Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
GL
Dova Pharmaceuticals to Present at Upcoming Investor Conferences
GL
Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
GL
Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DOVA Stock
  4. News Dova Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW